A Phase 3 interventional study of Cabozantinib and Zanzalintinib in Cancer, Renal Cell Carcinoma (RCC) and Pancreatic Neuroendocrine Tumors (pNET), sponsored by Exelixis. Enrolling by invitation at 4 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.
Drug: Cabozantinib · Drug: Zanzalintinib · Drug: Atezolizumab · Drug: Nivolumab · Drug: Abiraterone · Drug: Prednisone · Drug: Enzalutamide
Administered as specified in the parent study.
Also known as: XL184, Cabometyx
Administered as specified in the parent study.
Also known as: XL092
Administered as specified in the parent study.
Administered as specified in the parent study.
Administered as specified in the parent study.
Administered as specified in the parent study.
Administered as specified in the parent study.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for May 2030, 46 months after the start.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's planned 46 months is close to that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabozantinib · Zanzalintinib